Suzanne Rivera named new VP for research

Provost W.A. "Bud" Baeslack III announced, on November 4th, the appointment of Suzanne M. Rivera as Case Western Reserve´s new vice president for research, effective this month. Rivera, the university´s associate vice president for research since January 2011, emerged as the top choice after an extensive process involving campuswide nominations of internal university candidates. Since coming to CWRU, Rivera has distinguished herself through a commitment to collaboration and a focus on systems and processes.
Read more about her.


Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
December 9, 2014  

National Multiple Sclerosis Society

The Barancik Prize for Innovation in Multiple Sclerosis Research recognizes an exceptional scientist or a team of scientists whose work in MS research has demonstrated outstanding innovation and originality.

The prize is administered by the National Multiple Sclerosis Society. A selection committee comprised of leaders in science, medicine, and MS advocacy will review nominees. The committee will evaluate:
• Exceptional innovation and originality in scientific research relevant to MS
• Impact and potential of the research to lead to pathways for the treatment and cure for MS
• Scientific accomplishments that merit recognition as a future leader in MS research

For more information and guidelines , visit the Society’s website.

 
eRA Commons Usernames for Graduate and Undergraduate Students

Beginning next month, any students working for more than a calendar month on an NIH grant must have an eRA Commons ID. While this notice came out last year, enforcement, including rejection of progress reports, will begin in October 2014.

Read more at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-097.html.

 
The Commonwealth Fund

The Mongan Commonwealth Fund Fellowship in Minority Health Policy is a one-year, degree-granting, full-time fellowship at Harvard Medical School, Boston, beginning in July 2015.

The program is designed to prepare physicians for leadership roles in transforming health care delivery systems and promoting health policies and practices that improve access to high performance health care for racial and ethnic minorities, economically disadvantaged groups, and other vulnerable populations.

For more information and to download the brochure and application, visit the MCFF website.

 
The Ohio Clinical Trial Collaborative (OCTC)

The Ohio Clinical Trial Collaborative OCTC is developing partnerships with the drug industry to include Biotech and Pharmaceutical industries to perform clinical drug trials phase I-4. The OCTC is a network of Ohio based hospitals led by working groups in areas such as neuro oncology, pediatrics, infectious disease, and neuroscience. The OCTC was launched at the BIO2014 which was attended by 15,000 biotech and pharmaceutical executives in San Diego resulting in numerous leads for potential drug trials.

The OCTC has plans to attend additional biotech and pharmaceuticals shows. The OCTC is looking for additional working groups interested in developing a sell sheet that can then be searched on the World Wide Web and will begin sales and marketing activities to identify opportunities with industry. If there are companies that individuals would like OCTC to target, the group welcomes that feedback.

Review the OCTC working website at: http://ohioclintrials.org.

Contact Joe Peter at 216-702-5314 for more information.

 
The Cleveland Area Reliant IRB Review Process

The Cleveland Area Reliant Institutional Review Board (IRB) Review process includes participation by the Case Western Reserve University (CWRU) Social, Behavioral, and Educational Research (SBER) IRB, the Cleveland Clinic (CC) IRB, MetroHealth Medical Center (MHMC) IRB, and University Hospitals Case Medical Center (UHCMC) IRB. The process relies on executed IRB Authorization Agreements (IAA) between the institutions. These agreements document that all applicable human research subjects protection considerations will be made by one Institutional Review Board (IRB), which will be deemed the IRB of record. The IRBs of the other Cleveland area institutions will accept the approval of the IRB of record through the Reliant Review process. The goal is to eliminate duplication of effort and multiple applications for submission of the same protocol, and to encourage scientific collaboration among the affiliated institutions.

What types of studies are eligible for the Reliant Review Process?
Any type of human research study could be eligible for the Reliant Review process. These include but are not limited to investigator-initiated, federally-funded, foundation-supported, industry-sponsored, and non-funded studies.

The fundamental requirement is that a collaborating investigator must be named at each site where the research will occur. It is important for the Principal Investigator at the lead study site to work with the IRB of record throughout the Reliant Review Process to initiate acceptance of IRB approval at each collaborating site.

For further information, contact Kim Volarcik at (216) 368-0134 or kav6@case.edu.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.